Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AJANTPHARM.NS
BuyPremium GrowerAjanta Pharma Limited · Healthcare · India · $4.7B · Avg Vol: $4M/d
79
StockRankGet insider-trade alerts
Q
79
V
20
M
75
P/E (TTM)
38.9x
ROE
23.3%
D/E
0.1x
Dividend %
0.8%
COMPANY DESCRIPTION
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37.1B | 41.6B | 45.9B | 54.1B | 13.4% | 58.0B | 62.4B | 70.5B | 14.2% |
| EPS (INR) | 45.89 | 64.82 | 73.56 | 84.53 | 22.6% | 91.22 | 100.28 | 116.61 | 17.5% |
| Shares | 126.7M | 125.9M | 124.9M | 124.9M | -1.4% | 125.0M | — | — | — |
| Debt | 356.3M | 352.8M | 474.2M | 2.6B | 94.0% | 2.7B | — | — | — |
| Equity | 33.9B | 35.7B | 37.9B | 45.3B | 10.1% | — | — | — | — |
| Op CF | 7.9B | 7.9B | 11.6B | 5.3B | -12.6% | 5.3B | — | — | — |
| Inv CF | -5.6B | 653.9M | -3.8B | -4.3B | — | — | — | — | — |
| Fin CF | -1.1B | -10.5B | -7.3B | -1.7B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+5.0%
SMA 50SMA 200
Close
$37.04
RSI (14)
36.1
52W High
$39.78
From 52W High
0.9%
SCORE BREAKDOWN
Quality
79
ROIC
29.4%96.2
ROE
23.3%91.1
GP/Assets
72.5%94.9
Op. Margin
25.2%88.4
FCF/Assets
2.7%58.7
Piotroski
549.3
Int. Cover
50.0x89.2
D/E Ratio
0.06x69.3
Current Ratio
2.64x50.0
Value
20
P/E (TTM)
38.9x29.2
EV/EBITDA
28.3x22.7
P/FCF
273.6x6.4
P/B
9.8x12.4
P/S
7.6x31.1
Div Yield
0.8%23.5
Momentum
75
52W High %
93%90.3
RS 6M
23%82.0
SMA 50/200
1.15x83.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+28%41.0
Q Growth
31%64.2
FUNDAMENTALS
Market Cap
$4.7B
P/E (Forward)
30.3x
Gross Margin
77.2%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AJANTPHARM.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AJANTPHARM.NS | Ajanta Pharma Limited(you) | $4.7B | 79 | Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 79 | Buy |
| EMCURE.NS | Emcure Pharmaceuticals Limited | $3.9B | 81 | Strong Buy |
| GLAND.NS | Gland Pharma Limited | $5.1B | 88 | Strong Buy |
| IPCALAB.NS | Ipca Laboratories Limited | $5.3B | 91 | Strong Buy |
| ALKEM.NS | Alkem Laboratories Limited | $6.5B | 69 | Buy |
| LAURUSLABS.NS | Laurus Labs Limited | $11.1B | 75 | Buy |
| GRANULES.NS | Granules India Limited | $2.3B | 87 | Strong Buy |
| CAPLIPOINT.NS | Caplin Point Laboratories Limited | $2.2B | 86 | Strong Buy |
| NEULANDLAB.NS | Neuland Laboratories Limited | $3.2B | 64 | Hold |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%